SHIFTING THE LINES AGAINST CENTRAL NERVOUS SYSTEM DISORDERS ABOUT THERANEXUS Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Thanks to its knowledge of neuron and glial cell interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a solid and diversified portfolio of drug candidates in clinical-phase testing. The company’s combined drug repurposing strategy based on a solid commercial footing and a capability to rapidly demonstrate its clinical worth, enables it to produce different high-value-added proprietary drug candidates, significantly reduce development time and costs, and considerably increase the chance of its drugs reaching the market. Accordingly, THERANEXUS is well-positioned in several indications, including for Parkinson’s and Batten disease, for which there is currently no treatment available. Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX). THERANEXUSpublishes its cash position as of 30 September 2021 and presents its progress report 19/10/2021 Download PDF File (1440Ko) THERANEXUSannounces its first half 2021 results 30/09/2021 Download PDF File (497Ko) THERANEXUS and Beyond Batten Disease Foundation (BBDF) win US Investigational New Drug (IND) approval to start clinical development of BBDF 101 09/09/2021 Download PDF File (757Ko) THERANEXUS publishes its cash position as of June 30 2021 and presents an update on the progress of its main programs 08/07/2021 Download PDF File (1546Ko) Minutes of the combined general meeting of 16 June 2021 16/06/2021 Download PDF File (227Ko) Copyright © 2017 Theranexus | Site map | Legal notice © 2017 - 2021 Designed and produced by Actusnews ©